EMEA-001135-PIP01-11

Key facts

Invented name
Forsteo
Active substance
teriparatide
Therapeutic area
Endocrinology-Gynaecology-Fertility-Metabolism
Decision number
P/189/2011
PIP number
EMEA-001135-PIP01-11
Pharmaceutical form(s)
  • Solution for injection (in a pre-filled pen)
  • Transdermal system
Condition(s) / indication(s)
  • Treatment of fractures
  • Treatment of osteoporosis
Route(s) of administration
  • Subcutaneous use
  • Transdermal use
Contact for public enquiries
Eli Lilly & Company Limited

E-mail: eu_paediatric@lilly.com 
Tel. +44 (0)1276 483000

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

Related content

How useful was this page?

Add your rating